Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Strategies to genetically engineer T cells for cancer immunotherapy.

Literature DB >> 27138532

Strategies to genetically engineer T cells for cancer immunotherapy.

Timothy T Spear¹, Kaoru Nagato^2,3, Michael I Nishimura².

Abstract

Immunotherapy is one of the most promising and innovative approaches to treat cancer, viral infections, and other immune-modulated diseases. Adoptive immunotherapy using gene-modified T cells is an exciting and rapidly evolving field. Exploiting knowledge of basic T cell biology and immune cell receptor function has fostered innovative approaches to modify immune cell function. Highly translatable clinical technologies have been developed to redirect T cell specificity by introducing designed receptors. The ability to engineer T cells to manifest desired phenotypes and functions is now a thrilling reality. In this review, we focus on outlining different varieties of genetically engineered T cells, their respective advantages and disadvantages as tools for immunotherapy, and their promise and drawbacks in the clinic.

Entities: Chemical Disease Gene Species

Keywords: Adoptive cell therapy; Chimeric antigen receptor (CAR); Gene-modified T cells; T cell; T cell receptor (TCR); Tumor immunity

Mesh：

Substances：

Year: 2016 PMID： 27138532 PMCID： PMC5424608 DOI： 10.1007/s00262-016-1842-5

Source DB: PubMed Journal: Cancer Immunol Immunother ISSN： 0340-7004 Impact factor: 6.968

188 in total

1. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.

Authors: P K Darcy; M H Kershaw; J A Trapani; M J Smyth
Journal: Eur J Immunol Date: 1998-05 Impact factor: 5.532

2. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal: Blood Date: 2010-07-28 Impact factor: 22.113

3. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.

Authors: Y Reiter; A Di Carlo; L Fugger; J Engberg; I Pastan
Journal: Proc Natl Acad Sci U S A Date: 1997-04-29 Impact factor: 12.779

4. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors: Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal: J Immunother Date: 2013-02 Impact factor: 4.456

5. The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes.

Authors: Daniel F Legler; Caroline Johnson-Léger; Guido Wiedle; Claude Bron; Beat A Imhof
Journal: Eur J Immunol Date: 2004-06 Impact factor: 5.532

6. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors: Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal: Nat Med Date: 2007-07-01 Impact factor: 53.440

7. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors: Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal: J Exp Med Date: 2005-10-03 Impact factor: 14.307

8. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.

Authors: B K Cho; V P Rao; Q Ge; H N Eisen; J Chen
Journal: J Exp Med Date: 2000-08-21 Impact factor: 14.307

9. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

Authors: Mythili Koneru; Roisin O'Cearbhaill; Swati Pendharkar; David R Spriggs; Renier J Brentjens
Journal: J Transl Med Date: 2015-03-28 Impact factor: 5.531

10. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Authors: Eva Ellebaek; Trine Zeeberg Iversen; Niels Junker; Marco Donia; Lotte Engell-Noerregaard; Özcan Met; Lisbet Rosenkrantz Hölmich; Rikke Sick Andersen; Sine Reker Hadrup; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Journal: J Transl Med Date: 2012-08-21 Impact factor: 5.531

19 in total

1. Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors: Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal: Cancer Immunol Immunother Date: 2017-06-20 Impact factor: 6.968

Review 2. The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors: Souvik Karmakar; Karlyne M Reilly
Journal: CNS Oncol Date: 2016-12-21

3. A new therapeutic potential for cancers: One CAR with 2 different engines!

Authors: Abdolkarim Sheikhi; Abdollah Jafarzadeh
Journal: Hum Vaccin Immunother Date: 2017-05-11 Impact factor: 3.452

Review 4. IL-2 and Beyond in Cancer Immunotherapy.

Authors: John M Wrangle; Alicia Patterson; C Bryce Johnson; Daniel J Neitzke; Shikhar Mehrotra; Chadrick E Denlinger; Chrystal M Paulos; Zihai Li; David J Cole; Mark P Rubinstein
Journal: J Interferon Cytokine Res Date: 2018-02 Impact factor: 2.607

5. Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.

Authors: Timothy T Spear; Yuan Wang; Thomas W Smith; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal: Mol Ther Date: 2018-02-02 Impact factor: 11.454

Review 6. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms.

Authors: Iñaki Etxeberria; Irene Olivera; Elixabet Bolaños; Asunta Cirella; Álvaro Teijeira; Pedro Berraondo; Ignacio Melero
Journal: Cell Mol Immunol Date: 2020-05-20 Impact factor: 11.530

7. TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.

Authors: Timothy T Spear; Kendra C Foley; Elizabeth Garrett-Mayer; Michael I Nishimura
Journal: J Leukoc Biol Date: 2018-01-19 Impact factor: 4.962